Alabama is currently home to 1297 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
NTX-301 in MDS/AML
NCT04167917
Recruiting
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.
Gender:
Male
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Register for Updates
INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
NCT02977780
Recruiting
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : Abemaciclib Temozolomide (temodar) Neratinib CC115 QBS10072S
Gender:
All
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Glioblastoma
Register for Updates
Specimen Collection From Pregnant Women at Increased Risk for Fetal Aneuploidy
NCT01429389
Recruiting
The specimen collection is designed for the purpose of the development of a noninvasive prenatal test for T21.
Gender:
Female
Ages:
18 years and above
Trial Updated:
08/07/2023
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Down Syndrome, Fetal Aneuploidy
Register for Updates
Ridge Augmentation Using Allograft Particles Hydrated With or Without Recombinant Human Platelet-Derived Growth Factor
NCT04954664
Recruiting
This study will compare two techniques to achieve increase in ridge dimensions as a preparation for dental implants using a resorbable barrier membrane and bone particulate allogenic graft hydrated with saline or a growth factor called Recombinant Human Platelet-Derived Growth Factor (rhPDGF).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
08/04/2023
Locations: Unversity of Alabama at Birmingham, School of Dentistry, Birmingham, Alabama
Conditions: Dental Implant, Bone Loss
Register for Updates
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
NCT03403686
Recruiting
Results from large clinical trials demonstrate a strong association between lipid abnormalities and progression of the most common microvascular complication, diabetic retinopathy (DR). We found that activation of a master regulator of cholesterol metabolism, the nuclear hormone receptors liver X receptors (LXRα/LXRβ), prevents DR in rodent models. In this application, we seek to understand the mechanisms responsible for the beneficial effects of LXR agonists on retina and on bone marrow (BM) to... Read More
Gender:
All
Ages:
Between 21 years and 98 years
Trial Updated:
08/04/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Diabetic Retinopathy
Register for Updates
Autoantibody Reduction for Acute Exacerbations of Idiopathic Pulmonary Fibrosis
NCT03286556
Recruiting
Acute exacerbations (AE) are a dreaded manifestation of idiopathic pulmonary fibrosis (IPF) that presents with rapidly worsening respiratory function over days to weeks. AE account for about 1/2 the deaths in IPF patients, and are refractory to all medical therapies attempted to date. Considerable preliminary data shows pathological B-cell abnormalities and autoantibodies are present in AE-IPF and associated with disease severity. The experimental therapy here (therapeutic plasma exchange plus... Read More
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
08/04/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Idiopathic Pulmonary Fibrosis, Acute Fatal Form
Register for Updates
An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)
NCT05025332
Recruiting
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Pitt Hopkins Syndrome.
Gender:
All
Ages:
Between 3 years and 17 years
Trial Updated:
08/03/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pitt Hopkins Syndrome
Register for Updates
A Novel Non-Pharmacological Treatment of Diabetic Neuropathy
NCT05414968
Recruiting
The objective of the proposed work is to develop non-pharmacological interventions for diabetic peripheral neuropathy (DPN), to improve quality of life of individuals with diabetes, and reduce the prevalence of opiate prescription, sensation loss, falls, and deaths caused by DPN. To this end, the proposed study will investigate and determine the feasibility of the non-pharmacological intervention device. The feasibility study involves 16 participants, split evenly between pre-neuropathic diabeti... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: Auburn University, Auburn, Alabama
Conditions: Diabetic Peripheral Neuropathy
Register for Updates
Daily Adaptive Radiation Therapy an Individualized Approach for Carcinoma of the Cervix
NCT05197881
Recruiting
This is a single-arm, prospective, Phase II, multi-center clinical trial designed to demonstrate that adaptive radiotherapy for locally advanced cervical cancer will translate into a decreased rate of acute gastrointestinal toxicity compared with the historically reported rate for non-adaptive intensity modulated radiation therapy (IMRT). The timepoint for this assessment will be at week 5 of external beam radiotherapy (EBRT) and will use the Patient-Reported Outcomes version of the Common Termi... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
08/02/2023
Locations: University of Alabama Birmingham, Birmingham, Alabama
Conditions: Cervical Cancer by FIGO Stage 2018
Register for Updates
Beta-Agonist Versus OnabotulinumtoxinA Trial for Urgency Urinary Incontinence
NCT05806164
Recruiting
The goal of this clinical trial is to compare treatment outcomes between an oral medication (beta agonist) versus onabotulinumtoxinA injections in women with urgency urinary incontinence (UUI). Participants will be randomly selected to receive one of the two treatments. The primary outcome measure will be at 3 months, and women will be followed for a total of 12 months. Based on patient expert input, there are 2 primary outcomes: Treatment satisfaction and urinary symptom severity.
Gender:
Female
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Urgency Urinary Incontinence
Register for Updates
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT03767348
Recruiting
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Gender:
All
Ages:
18 years and above
Trial Updated:
08/01/2023
Locations: University of Birmingham Alabama, Birmingham, Alabama
Conditions: Cancer, Melanoma (Skin), Mismatch Repair Deficiency, Microsatellite Instability, Non-melanoma Skin Cancer, Cutaneous Melanoma, NSCLC
Register for Updates
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT05501886
Recruiting
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/30/2023
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Breast Cancer
Register for Updates